Ionis Pharmaceuticals, Inc. (IONS)

Market Cap	6.80B
Revenue (ttm)	944.05M
Net Income (ttm)	-268.22M
Shares Out	159.39M
EPS (ttm)	-1.73
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,859,935
Open	43.68
Previous Close	43.24
Day's Range	42.09 - 43.72
52-Week Range	23.95 - 50.43
Beta	0.25
Analysts	Buy
Price Target	60.13 (+40.85%)
Earnings Date	Jul 30, 2025

About IONS

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSE...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 17, 1991
• Employees: 1,069
• Stock Exchange: NASDAQ
• Ticker Symbol: IONS
• Website: https://www.ionis.com

Financial Performance

In 2024, Ionis Pharmaceuticals's revenue was $705.14 million, a decrease of -10.48% compared to the previous year's $787.65 million. Losses were -$453.90 million, 23.9% more than in 2023.

Analyst Summary

According to 15 analysts, the average rating for IONS stock is "Buy." The 12-month stock price target is $60.13, which is an increase of 40.85% from the latest price.

Price Target

$60.13

(40.85% upside)

Analyst Consensus: Buy